State Senator Devlin Robinson | Pennsylvania
State Senator Devlin Robinson | Pennsylvania
Legislation to improve cancer treatment access was signed into law this week, according to Sen. Devlin Robinson (R-37). Act 39 of 2024, the companion bill to Robinson’s Senate Bill 954, aims to provide Pennsylvanians better access to personalized treatments following a diagnosis of cancer and other specific diseases through biomarker testing and precision medicine.
Biomarker testing looks for biological changes at a molecular level, helping to detect cancer and other conditions such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. This ensures patients receive the appropriate treatment options and predicts the growth and spread of disease.
“It was an honor to work with Rep. Mullins to write legislation with the shared goal of improving cancer treatment access,” said Robinson. “Act 39 of 2024 is a significant step forward in ensuring that patients receive the most effective, personalized treatment options available. By expanding access to biomarker testing and precision medicine, we can detect diseases and tailor treatments to the individual needs of each patient. It addresses critical disparities in care, ensuring that all Pennsylvanians have access to these life-saving advancements.”
The law takes effect in 60 days.
CONTACT:
Allison Dutrey
Alerts Sign-up